ABSTRACT
Limitations on use of nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids in the pharmacotherapy of osteoarthritis (OA) leave few pharmacological options for many OA patients. Results of a recent study on the use of transdermal buprenorphine patches in OA management are discussed.